Brivanib alaninate (
INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by
Bristol-Myers Squibb for the treatment of
hepatocellular carcinoma or HCC (also called
malignant hepatoma), the most common type of
liver cancer.
Brivanib alaninate also inhibits VEGFR and
fibroblast growth factor receptors (FGFR), which is known to play a major role in the etiopathogenesis of HCC. To date, brivanib alaninate has been investigated in 29 studies, including more than 4,000 patients around the world.
[citation needed]
Hepatocellular carcinoma (summary)[edit]
Hepatocellular carcinoma
[1] is a primary cancer of the liver and is more common in men than in women. The disease occurs mostly in people who have scarring of the liver (
cirrhosis) or after infection with
hepatitis B or
hepatitis C. Symptoms include pain and swelling in the abdomen, weight loss, weakness, loss of appetite and nausea. Hepatocellular carcinoma is a severe and life-threatening disease that is associated with poor overall survival.
[2] While the choice of treatment depends mainly on how advanced the disease is, the only proven therapies to cure the cancer is surgery to remove the tumor and liver transplantation, but these therapies can only be carried out in very few patients. Other treatments include
chemotherapy and
immunotherapy.
Radiofrequency ablation and ethanol injection are also used to remove small tumors.
[3]
As a result of poor liver function,
metastases, or both, only 10% to 20% of patients undergo surgery. In patients having surgery, the 5-year survival rate is only 25% to 50%. Several
chemotherapeutic agents have been evaluated for the treatment of hepatocellular carcinoma.
Doxorubicin (trade name
Adriamycin; also known as
hydroxydaunorubicin), the most widely used agent in HCC, has shown a 4% to 10.5% response rate in patients with HCC. Studies have shown that the overall response (OR) rate, but not
overall survival (OS), doubles when doxorubicin was given in combination with
cisplatin,
IFN, and
5-fluorouracil. The multitargeted
tyrosine kinase inhibitor sorafenib (trade name
Nexavar), which inhibits
vascular endothelial growth factor receptor (VEGFR),
platelet-derived growth factor receptor, raf,
c-kit, and flt-3, has been shown to inhibit HCC-induced proliferation and
angiogenesis. Sorafenib has also been shown to provide a significant improvement in OS in patients with HCC. Based on these results, researchers concluded that this class of agents may be effective in the treatment of HCC.
Biological activity[edit]
BMS-540215 is an ATP-competitive inhibitor of human
VEGFR-2, with an IC
50 of 25 nmol/L and K
i of 26 nmol/L. In addition, it inhibits
VEGFR-1 (IC
50 = 380 nmol/L) and
VEGFR-3 (IC
50 = 10 nmol/L). BMS-540215 also showed good selectivity for FGFR-1 (IC
50 = 148 nmol/L), FGFR-2 (IC
50 = 125 nmol/L), and FGFR-3 (IC
50 = 68 nmol/L). Furthermore, BMS-540215 has been shown to selectively inhibit the proliferation of
endothelial cells stimulated by
VEGF and FGF
in vitro with IC
50 values of 40 and 276 nmol/L, respectively.
[6][7] It also shows
broad-spectrum in vivo antitumor activity over multiple dose levels and induces stasis in large tumors, suggesting that it may have a role in the treatment of hepatocellular carcinoma (HCC).
Pharmacokinetic and pharmacodynamic profiles[edit]
BMS-582664 was originally prepared in an effort to improve the
aqueous solubility and oral
bioavailability of the
parent compound BMS-540215. Both BMS-540215 and its orally active ester prodrug BMS-582664 (brivanib alaninate), demonstrate
broad-spectrum in vivo antitumor activity over multiple dose levels as well as being effective at inducing stasis in large tumors. Brivanib alaninate can also be safely dosed in combination with other targeted and
cytotoxic drugs including
paclitaxelresulting in enhanced antitumor activity as observed by a long period of tumor growth inhibition. Overall survival was significantly extended by brivanib versus sorafenib, both first- line and when second.
Mechanisms of action[edit]
The exact mechanisms by which brivanib treatment induces growth inhibition are not well understood. Ongoing research has shown that brivanib affects the host endothelium based on both in vitro and in vivo effects). Brivanib may prevent the tumor mass from expanding by cutting off the supply of nutrients and growth factors to the tumor cells.
A recent study showed that brivanib effectively inhibits tumor growth and that brivanib-induced
growth inhibition is associated with inactivation of VEGFR-2, increased apoptosis, a reduction in microvessel density, inhibition of cell proliferation, and
down-regulation of cell cycle regulators, including cyclin D1, Cdk-2, Cdk-4, cyclin B1, and phospho-c-Myc.
[4] Based on this study, researchers have concluded that cell cycle arrest due to a reduction in positive cell cycle regulators may be responsible for the observed growth inhibition. The same study showed that treatment with brivanib also led to a decrease in the number of proliferating cells compared with control.
Doses required for achieving complete tumor stasis do not produce overt
toxicity as defined by weight loss, mortality or unkempt appearance and behavior. The
prodrugbrivanib alaninate, which is completely
hydrolyzed to BMS-540215
in vivo, has
pharmacokinetic properties suitable for once a day or twice daily oral dosing. Completed and ongoing clinical trials show that brivanib alaninate appears to be tolerable and may exhibits favorable
pharmacokinetic and
pharmacodynamic profiles with evidence of target inhibition in surrogate tissues. Clinical and pharmacodynamic data support an oral once daily administration at 800 mg. The
investigational drugshows promising activity as single agent in HCC. Brivanib also shows promising activity in combination with
cetuximab in
colorectal cancer.
[8] Further evaluations are currently ongoing.
Safety profile[edit]
Ongoing clinical trials have shown brivanib to have a manageable safety profile. The trial drug is one of the first agents to demonstrate promising antitumor activity in advanced HCC patients treated with prior sorafenib.
[9]
Adverse reactions[edit]
In clinical trials, brivanib was generally well tolerated. The most common adverse events included fatigue, hypertension, and diarrhea.
[10]
Ongoing clinical development program[edit]
To further investigate the benefits of brivanib in patients with advanced HCC, a broad-spectrum, global, phase III clinical development plan called the
Brivanib studies in HCC patients at RISK (
BRISK), has been initiated.
[citation needed] ~
[11][12]
Clinical benefits seen with brivanib in the first-line setting, and following the failure of sorafenib therapy, highlight the potential to improve the clinical course of patients with advanced HCC.
[citation needed]
Regulatory status[edit]
On 27 October 2011,
orphan designation (EU/3/11/918) was granted by the
European Commission to Bristol-Myers Squibb for brivanib alaninate for the treatment of hepatocellular carcinoma.
[13] At the time of the orphan designation, several medicines were authorized in the EU for the treatment of hepatocellular carcinoma.
Submission and application[edit]
At the time of submission of the application for orphan designation, clinical trials with brivanib alaninate in patients with hepatocellular carcinoma were ongoing. As part of the submission process, Bristol-Myers Squibb has provided sufficient information to show that brivanib alaninate might be of significant benefit for patients with hepatocellular carcinoma because it could provide an alternative for patients who cannot take or for whom existing treatments do not work. Early studies show that it might improve the treatment of patients with this condition, particularly if used when existing treatment had failed. However, this assumption needs to be confirmed at the time of EU marketing authorization, in order to maintain the orphan status.
